The Contemporary Role of Beta Blockers in Patients With Acute Myocardial Infarction

Influence of Beta-Blockers on Prognosis in Patients With Acute Myocardial Infarction Complicated With Normal Ejection Fraction

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04564365

Enrollment

1000

Registered

2020-09-25

Start date

2019-06-30

Completion date

2021-12-25

Last updated

2021-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Keywords

left ventricular ejection fraction, acute myocardial infarction, beta-blocker

Brief summary

The use of beta blockers after acute myocardial infarction is a core component of drug therapy, but evidence is primarily derived from patients who did not receive reperfusion therapy and secondary prophylaxis.In contemporary times, the prognostic value of beta blockers in patients with acute myocardial infarction has been questioned, particularly in patients without reduced heart failure/ejection fraction after acute myocardial infarction.

Interventions

DRUGbeta-blocker

To investigate the relationship between the use of beta blockers and prognosis in patients with normal ejection fraction after acute myocardial infarction

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* The diagnosis of acute myocardial infarction was clear and the left ventricular ejection fraction was normal

Exclusion criteria

* History of heart failure Died in hospital

Design outcomes

Primary

Measure	Time frame	Description
mortality	the median time of 8 months	all-cause mortality

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026